Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Starpharma Holdings Limited (ASX:SPL) Announce Final Report and Annual Results

Abstract:
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced its full year financial results for the year ended 30 June 2008.

Starpharma Holdings Limited (ASX:SPL) Announce Final Report and Annual Results

Melbourne, Australia | Posted on August 27th, 2008

Total operating and investing outflows for the year were A$5.4 million, and at the end of June 2008 the Company held cash reserves of A$7.5 million. Net cash outflows for the year of A$2.0 million included a financing inflow of A$3.4 million.

The net loss for the period was A$7.5 million, compared with A$7.2 million for the previous year.

Revenue from ordinary activities increased by 17% to A$1.7 million over the period, consisting of royalty and licensing revenue of A$1.4 million, and interest revenue on cash held. Other income of A$8.2 million consisted of grant income from United States and Australian Government grants. The majority of US Government grants were from the National Institutes of Health (NIH).

Further details of the financial results are included in the Preliminary Final Report to Australian Securities Exchange (ASX).

During this reporting period the Company has made substantial progress as highlighted by the following announcements over the year:

Commercial development

- The signing of an agreement with leading condom company SSL International plc, owner of the Durex(R) brand, for co-development of VivaGel(R)-coated condoms.

- The signing of a collaborative research agreement with Stiefel - the world's largest privately-owned dermatology pharmaceutical company.

- First commercial product launch of Priostar(R) Dendrimers - EMD Chemicals Inc. launch a research reagent kit called NanoJuiceTM Transfection Kit. VivaGel(R): Clinical Development and New Indications

- Clinical trial demonstrates that VivaGel(R) is safe and well-tolerated in women following twice daily dosing for 14 days - 54 sexually abstinent women tested in double-blind study in US and Kenya.

- Potential to expand VivaGel(R) applications to genital warts and cervical cancer - pre-clinical data demonstrates the active ingredient in VivaGel(R), SPL7013, inhibits clinically-relevant strains of human papillomavirus (HPV).

Pipeline and Application development

- SPL7013, the active ingredient in VivaGel(R), found to have potential application for arthritis and dermatology treatments.

- Starpharma and Baker IDI Heart and Diabetes Institute awarded funding for codevelopment of arterial disease imaging agent.

- US$1.3 million US Defense Department contract awarded to DNT and Central Michigan University Research Corporation to develop water purification technology.

- Dendrimer technology applications expanded to food science with Unilever agreement to co-develop a research tool using Starpharma's Priostar(R) dendrimer technology.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

For more information, please click here

Contacts:
Dr Jackie Fairley
Chief Executive Officer
TEL: +61-3-8532-2704

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Graphene is strong, but is it tough? Berkeley Lab scientists find that polycrystalline graphene is not very resistant to fracture February 7th, 2016

Lithium battery catalyst found to harm key soil microorganism February 7th, 2016

Scientists take key step toward custom-made nanoscale chemical factories: Berkeley Lab researchers part of team that creates new function in tiny protein shell structures February 6th, 2016

Discovery of the specific properties of graphite-based carbon materials February 6th, 2016

Nanomedicine

Scientists take key step toward custom-made nanoscale chemical factories: Berkeley Lab researchers part of team that creates new function in tiny protein shell structures February 6th, 2016

Study reveals how herpes virus tricks the immune system February 5th, 2016

Hepatitis virus-like particles as potential cancer treatment February 5th, 2016

Researchers discover new phase of boron nitride and a new way to create pure c-BN February 5th, 2016

Announcements

Graphene is strong, but is it tough? Berkeley Lab scientists find that polycrystalline graphene is not very resistant to fracture February 7th, 2016

Lithium battery catalyst found to harm key soil microorganism February 7th, 2016

Scientists take key step toward custom-made nanoscale chemical factories: Berkeley Lab researchers part of team that creates new function in tiny protein shell structures February 6th, 2016

Discovery of the specific properties of graphite-based carbon materials February 6th, 2016

Financial Reports

Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015

Haydale Announce Year End Results November 3rd, 2015

Harris & Harris Group to Host Conference Call on Third-Quarter 2015 Financial Results on November 12, 2015 October 23rd, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic